Control strategies for synthetic therapeutic peptide APIs – Part II: Raw material considerations
![](https://www.polypeptide.com/wp-content/uploads/2022/09/polypeptide-logo.png)
Expert views
I. Eggen, B. Gregg, H. Rode, A. Swietlow, M. Verlander, A. Szajek; BioPharm International, May 2014
I. Eggen, B. Gregg, H. Rode, A. Swietlow, M. Verlander, A. Szajek; BioPharm International, May 2014